A Phase I Safety and Tolerability Study of Peri-Lymphatically Ultralow Dose IRX-2 in Patients with Squamous Cell Carcinoma of the Head and Neck Who Have Failed Surgery And/Or Radiation Therapy

  • Kenady, Daniel (PI)

Grants and Contracts Details

StatusFinished
Effective start/end date10/1/049/30/07